Health Condition 1: C509- Malignant neoplasm of breast of unspecified site
Conditions
Interventions
Intervention1: Not applicable: Not applicable
Sponsors
Government Ministry of Human Resources and Development Uchchatar Avishkar Yojana
Private Centre of Excellence Merck at Proteomics lab IIT Bombay
Eligibility
Inclusion criteria
Inclusion criteria: 1. Histologically confirmed TNBC 2. Treatment naive 3. Tumour and adjacent normal tissue sample preserved by TMH/ACTREC Tumour Tissue Repository 4. Patient consented for study by TMH/ACTREC Tumour Tissue Repository 5. Patient already consented for IEC Study 254 : A prospective approval of the peri-operative Hypoxia in breast cancer (Sample B study) & tissue available for OMICS assays
Exclusion criteria
Exclusion criteria: 1. Patients who have received any form of prior treatment 2. Patients not consented by TMH/ACTREC Tumour Tissue Repository or on IEC Study 254 3. Patients whose clinical history is not available 4. Patients for whom paired normal tissue or blood is not collected
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Using a patient centric and patient specific multi-omics approach to holistically characterize molecular programs involved in development of Triple Negative Breast Cancer (TNBC).Timepoint: 12 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Not applicableTimepoint: Not applicable | — |
Countries
India
Contacts
Public ContactYogesh Kembhavi
Tata Memorial Centre
Outcome results
None listed